Mark R. Gilbert, M.D.

Affiliations: 
Neuro-Oncology University of Texas, MD Anderson Cancer Center 
Website:
http://faculty.mdanderson.org/Mark_Gilbert/
Google:
"Mark Gilbert"
Mean distance: 106866
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Soffietti R, Bettegowda C, Mellinghoff IK, et al. (2022) Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. Neuro-Oncology
Doucet-O'Hare TT, Rosenblum JS, Shah AH, et al. (2021) Endogenous Retroviral Elements in Human Development and Central Nervous System Embryonal Tumors. Journal of Personalized Medicine. 11
Yu G, Pang Y, Merchant M, et al. (2021) Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas. Cancers. 13
Ruiz-Rodado V, Dowdy T, Lita A, et al. (2021) Cysteine is a limiting factor for glioma proliferation and survival. Molecular Oncology
Yuan Y, Wu J, Gilbert MR. (2021) BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials. Neuro-Oncology Practice. 8: 627-638
Patil N, Somasundaram E, Waite KA, et al. (2021) Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. Journal of Neuro-Oncology
Arakaki AKS, Szulzewsky F, Gilbert MR, et al. (2021) Utilizing preclinical models to develop targeted therapies for rare central nervous system cancers. Neuro-Oncology. 23: S4-S15
Armstrong TS, Gilbert MR. (2021) Clinical trial challenges, design considerations, and outcome measures in rare CNS tumors. Neuro-Oncology. 23: S30-S38
Wu Z, Abdullaev Z, Pratt D, et al. (2021) Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. Neuro-Oncology
Vezina A, Manglani M, Morris D, et al. (2021) Adenosine A2A receptor activation enhances blood-tumor barrier permeability in a rodent glioma model. Molecular Cancer Research : McR
See more...